Vitamin D Supplements for Prevention of Tuberculosis Infection and Disease.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Vitamin D metabolites support innate immune responses to Mycobacterium tuberculosis.

Who Took Part

PubMed indexes the participants as children, both men and women.

The primary outcome was a positive QFT result at the 3-year follow-up, expressed as a proportion of children.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Secondary outcomes included the serum 25-hydroxyvitamin D (25[OH]D) level at the end of the trial and the incidence of tuberculosis disease, acute respiratory infection, and adverse events.

What Was Measured

The subject headings attached to it are Cholecalciferol, Dietary Supplements, Incidence, Latent Tuberculosis, Mycobacterium tuberculosis, Respiratory Tract Infections and Treatment Failure.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2020 (The New England journal of medicine), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.